Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Biologics Market: by Drug Class, by Therapeutic Application, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027

Published by Coherent Market Insights Product code 931959
Published Content info 317 Pages
Delivery time: 2-3 business days
Price
Back to Top
Biologics Market: by Drug Class, by Therapeutic Application, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027
Published: April 3, 2020 Content info: 317 Pages
Description

Biological products include wide range of products such as vaccines, blood and blood components, allergenic, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins. Many biologics are produced using recombinant DNA technology. Biologics are the best used drugs for the treatment of genetic disorders. Biologics are also used to treat children with CLN2 disease, which is a form of Batten disease. Moreover, in 2017, BioMarin Pharmaceutical Inc. received the U.S. FDA approval for its Brineura (cerliponase alfa), which is indicated for the treatment CLN2 disease.

Market Dynamics

In the recent past, several novel biopharmaceutical products were approved by major regulatory bodies and major players in the market have launched various novel and innovative biopharmaceutical products. Rapid approvals and launches of novel products in the market are expected to be major drivers for growth of the biologics market. For instance, in 2017, Amgen Inc. received the U.S. Food and Drug Administration (FDA) for its Blincyto (Blinatumomab) for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults and children.

Furthermore, in 2017, Janssen Biotech, Inc. received the U.S FDA approval for Darzalex (daratumumab) in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma.

However, high cost of biologics for the treatment of diseases such as rheumatoid arthritis, cancer, multiple sclerosis, psoriasis, and other diseases is expected to hamper biologics market growth over the forecast period. For instance, according to the data published in NCBI in 2018, the cost of biologics for treatment of serious diseases such as cancer, diabetes, rheumatoid arthritis, and other inflammatory diseases can range from US$ 10,000 to US$ 30,000 per year in the U.S. and can exceed US$ 500,000 per year for the most expensive biologics.

Furthermore, it is more difficult to manufacture biologics than chemical drugs, as they are extremely sensitive due to its very complex molecules.

Key features of the study:

This report provides in-depth analysis of the global biologics market, market size (US$ Bn), and compound annual growth rate (CAGR (%) for the forecast period, 2020-2027, considering 2019 as the base year

It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market

This study provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players

It profiles key players in the global biologics market based on the following parameters: company overview, financial performance, product portfolio, geographical presence, key developments, and strategies

Key players covered as a part of this study include Bristol-Myers Squibb Company (BMS), Merck & Co., Inc., Roche AG, Merck KGaA, AstraZeneca Plc, Regeneron Pharmaceuticals, Inc, Novartis International AG, Pfizer, Inc., Amgen, Inc., AbbVie, Inc., Sanofi S.A., Eli Lilly & Company, Novo Nordisk A/S, Johnson & Johnson, GlaxoSmithKline Plc, Teva Pharmaceutical Industries Ltd., Ipsen S.A., and Allergan Plc.

Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics

The global biologics market report caters to various stakeholders in this industry, which include investors, product manufacturers, distributors, and suppliers for Global Biologics Market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Biologics Market, by Drug Class:
  • Monoclonal Antibody
  • Vaccine
  • Recombinant Insulin
  • Human Growth Hormone
  • Blood Factor
  • Fusion Protein
  • Erythropoietin
  • Recombinant Enzyme
  • Interferon
  • Colony-stimulating Factor
  • Cell Therapy
  • Gene Therapy
  • Oligonucleotides
  • Others
  • Global Biologics Market, By Therapeutic Application:
  • Oncology
  • Metabolic Disorders
  • Autoimmune/Immunologic Diseases
  • Ophthalmic Diseases
  • Inflammatory Bowel Diseases (IBDs)
  • Respiratory Disorders
  • Neurological Disorders
  • Musculoskeletal Disorders (MSDs)
  • Cardiovascular Diseases (CVDs)
  • Infectious Diseases
  • Others
  • Global Biologics Market, by Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Global Biologics Market, by Region:
  • North America
  • By Country:
  • U.S.
  • Canada
  • By Drug Class:
  • Monoclonal Antibody
  • Vaccine
  • Recombinant Insulin
  • Human Growth Hormone
  • Blood Factor
  • Fusion Protein
  • Erythropoietin
  • Recombinant Enzyme
  • Interferon
  • Colony-stimulating Factor
  • Gene Therapy
  • Cell Therapy
  • Oligonucleotides
  • Others
  • By Therapeutic Application:
  • Oncology
  • Metabolic Disorders
  • Autoimmune/Immunologic Diseases
  • Ophthalmic Diseases
  • Inflammatory Bowel Diseases (IBDs)
  • Respiratory Disorders
  • Neurological Disorders
  • Musculoskeletal Disorders (MSDs)
  • Cardiovascular Diseases (CVDs)
  • Infectious Diseases
  • Others
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Europe
  • By Country:
  • U.K.
  • Germany
  • Italy
  • Spain
  • France
  • Russia
  • Rest of Europe
  • By Drug Class:
  • Monoclonal Antibody
  • Vaccine
  • Recombinant Insulin
  • Human Growth Hormone
  • Blood Factor
  • Fusion Protein
  • Erythropoietin
  • Recombinant Enzyme
  • Interferon
  • Colony-stimulating Factor
  • Gene Therapy
  • Cell Therapy
  • Oligonucleotides
  • Others
  • By Therapeutic Application:
  • Oncology
  • Metabolic Disorders
  • Autoimmune/Immunologic Diseases
  • Ophthalmic Diseases
  • Inflammatory Bowel Diseases (IBDs)
  • Respiratory Disorders
  • Neurological Disorders
  • Musculoskeletal Disorders (MSDs)
  • Cardiovascular Diseases (CVDs)
  • Infectious Diseases
  • Others
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Asia Pacific
  • By Country:
  • Australia
  • India
  • China
  • Japan
  • ASEAN
  • South Korea
  • Rest of Asia Pacific
  • By Drug Class:
  • Monoclonal Antibody
  • Vaccine
  • Recombinant Insulin
  • Human Growth Hormone
  • Blood Factor
  • Fusion Protein
  • Erythropoietin
  • Recombinant Enzyme
  • Interferon
  • Colony-stimulating Factor
  • Gene Therapy
  • Cell Therapy
  • Oligonucleotides
  • Others
  • By Therapeutic Application:
  • Oncology
  • Metabolic Disorders
  • Autoimmune/Immunologic Diseases
  • Ophthalmic Diseases
  • Inflammatory Bowel Diseases (IBDs)
  • Respiratory Disorders
  • Neurological Disorders
  • Musculoskeletal Disorders (MSDs)
  • Cardiovascular Diseases (CVDs)
  • Infectious Diseases
  • Others
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Latin America
  • By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • By Drug Class:
  • Monoclonal Antibody
  • Vaccine
  • Recombinant Insulin
  • Human Growth Hormone
  • Blood Factor
  • Fusion Protein
  • Erythropoietin
  • Recombinant Enzyme
  • Interferon
  • Colony-stimulating Factor
  • Gene Therapy
  • Cell Therapy
  • Oligonucleotides
  • Others
  • By Therapeutic Application:
  • Oncology
  • Metabolic Disorders
  • Autoimmune/Immunologic Diseases
  • Ophthalmic Diseases
  • Inflammatory Bowel Diseases (IBDs)
  • Respiratory Disorders
  • Neurological Disorders
  • Musculoskeletal Disorders (MSDs)
  • Cardiovascular Diseases (CVDs)
  • Infectious Diseases
  • Others
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Middle East
  • By Country:
  • GCC
  • Israel
  • Rest of Middle East
  • By Drug Class:
  • Monoclonal Antibody
  • Vaccine
  • Recombinant Insulin
  • Human Growth Hormone
  • Blood Factor
  • Fusion Protein
  • Erythropoietin
  • Recombinant Enzyme
  • Interferon
  • Colony-stimulating Factor
  • Gene Therapy
  • Cell Therapy
  • Oligonucleotides
  • Others
  • By Therapeutic Application:
  • Oncology
  • Metabolic Disorders
  • Autoimmune/Immunologic Diseases
  • Ophthalmic Diseases
  • Inflammatory Bowel Diseases (IBDs)
  • Respiratory Disorders
  • Neurological Disorders
  • Musculoskeletal Disorders (MSDs)
  • Cardiovascular Diseases (CVDs)
  • Infectious Diseases
  • Others
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Africa
  • By Country/Region:
  • South Africa
  • Central Africa
  • North Africa
  • By Drug Class:
  • Monoclonal Antibody
  • Vaccine
  • Recombinant Insulin
  • Human Growth Hormone
  • Blood Factor
  • Fusion Protein
  • Erythropoietin
  • Recombinant Enzyme
  • Interferon
  • Colony-stimulating Factor
  • Gene Therapy
  • Cell Therapy
  • Oligonucleotides
  • Others
  • By Therapeutic Application:
  • Oncology
  • Metabolic Disorders
  • Autoimmune/Immunologic Diseases
  • Ophthalmic Diseases
  • Inflammatory Bowel Diseases (IBDs)
  • Respiratory Disorders
  • Neurological Disorders
  • Musculoskeletal Disorders (MSDs)
  • Cardiovascular Diseases (CVDs)
  • Infectious Diseases
  • Others
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Company Profiles
  • Bristol-Myers Squibb Company (BMS) *
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • Merck & Co., Inc.
  • Roche AG
  • Merck KGaA
  • AstraZeneca Plc
  • Regeneron Pharmaceuticals, Inc
  • Novartis International AG
  • Pfizer, Inc.
  • Amgen, Inc.
  • AbbVie, Inc.
  • Sanofi S.A.
  • Eli Lilly & Company
  • Novo Nordisk A/S
  • Johnson & Johnson
  • GlaxoSmithKline Plc
  • Teva Pharmaceutical Industries Ltd.
  • Ipsen S.A.
  • Allergan Plc.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Class
    • Market Snippet, By Therapeutic Application
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Biologics & Biosimilars Overview
  • Impact Analysis
  • Patent Expiry Analysis
  • Pipeline Analysis
  • Regulatory Scenario
  • Reimbursement Scenario
  • Product Approval/Launch
  • Collaboration-Acquisition
  • Market Trends
  • PEST Analysis
  • Epidemiology

4. Global Biologics Market, By Drug Class, 2019 - 2027, (US$ Billion)

  • Introduction
    • Market Share Analysis, 2019 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Monoclonal Antibody
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Billion)
  • Vaccine
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Billion)
  • Recombinant Insulin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Billion)
  • Human Growth Hormone
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Billion)
  • Blood Factor
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Billion)
  • Fusion Protein
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Billion)
  • Erythropoietin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Billion)
  • Interferon
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Billion)
  • Recombinant Enzyme
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Billion)
  • Colony-stimulating Factor
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Billion)
  • Cell Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Billion)
  • Gene Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Billion)
  • Oligonucleotides
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Billion)
  • Others (Peptide, Botulinum Toxin, and Others)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Billion)

5. Global Biologics Market, By Therapeutic Application, 2019 - 2027, (US$ Billion)

  • Introduction
    • Market Share Analysis, 2019 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Oncology
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Billion)
  • Metabolic Disorders
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Billion)
  • Autoimmune/Immunologic Diseases
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Billion)
  • Ophthalmic Diseases
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Billion)
  • Inflammatory Bowel Diseases (IBDs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Billion)
  • Respiratory Disorders
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Billion)
  • Neurological Disorders
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Billion)
  • Musculoskeletal Disorders (MSDs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Billion)
  • Cardiovascular Diseases (CVDs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Billion)
  • Infectious Diseases
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Billion)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Billion)

6. Global Biologics Market, By Distribution Channel, 2019 - 2027, (US$ Billion)

  • Introduction
    • Market Share Analysis, 2019 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Billion)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Billion)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Billion)

7. Global Biologics Market, By Region, 2019 - 2027 (US$ Billion)

  • Introduction
    • Market Share Analysis, 2019 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Regional Trends
  • North America
    • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Billion)
    • Market Size and Forecast, By Therapeutic Application, 2016 - 2027, (US$ Billion)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Billion)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Billion)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Billion)
    • Market Size and Forecast, By Therapeutic Application, 2016 - 2027, (US$ Billion)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Billion)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Billion)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Billion)
    • Market Size and Forecast, By Therapeutic Application, 2016 - 2027, (US$ Billion)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Billion)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Billion)
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Billion)
    • Market Size and Forecast, By Therapeutic Application, 2016 - 2027, (US$ Billion)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Billion)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Billion)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Africa
    • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Billion)
    • Market Size and Forecast, By Therapeutic Application, 2016 - 2027, (US$ Billion)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Billion)
    • Market Size and Forecast, By Country/Region, 2016 - 2027, (US$ Billion)
    • North Africa
    • Central Africa
    • South Africa
  • Middle East
    • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Billion)
    • Market Size and Forecast, By Therapeutic Application, 2016 - 2027, (US$ Billion)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Billion)
    • Market Size and Forecast, By Country/Region, 2016 - 2027, (US$ Billion)
    • GCC
    • Israel
    • Rest of Middle East

8. Competitive Landscape

  • Company Profiles
    • Bristol-Myers Squibb Company (BMS)
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Merck & Co., Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Roche AG
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Merck KGaA
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • AstraZeneca Plc
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Regeneron Pharmaceuticals, Inc
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Novartis International AG
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Pfizer, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Amgen, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • AbbVie, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Sanofi S.A.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Eli Lilly & Company
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Novo Nordisk A/S
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Johnson & Johnson
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • GlaxoSmithKline Plc
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Teva Pharmaceutical Industries Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Ipsen S.A.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Allergan Plc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies

9. Section

  • References
  • Research Methodology
  • About Us and Sales Contact
Back to Top